Overview

Price chart · mood · technical indicators

BIIB

Biogen Incstock Healthcare

Drug Manufacturers - General

$187.2160.26%Current Market Mood:Strong Bullish

Market Mood

Price Range (1Y)

$115.25$202.41

Current: $187.21

Idea: EMA

1Y Return

+23.9%

Sharpe 3Y

0.52

Market Comparison

vs Healthcare Sector & Drug Manufacturers - General Industry

BIIB

+60.26%

1Y Performance

Healthcare

Sector 1Y

Drug Manufacturers - General

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio20.11Forward 13.40

EPS (TTM)$9.3031.1% YoY

Profit margin13.8%HEALTHCARE

Market cap$27.62BLarge cap

Wall Street coverage

$217.03median target· current $221.42 (-2.0%)36 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 13.40
PEG ratio: 3.94
P/B: 1.48
P/S (TTM): 2.78
EV/EBITDA: 11.08

Profitability & growth

ROE (TTM): 7.7%
Operating margin: 22.9%
Revenue growth YoY: 1.9%
Dividend yield: —
Beta: 0.16

Last earnings

Feb 6, 2026 · Estimate $1.61 · Reported $1.99

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Biogen Inc

Company profile

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.

Classification

Sector: Healthcare
Industry: Drug Manufacturers - General
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 225 BINNEY STREET, CAMBRIDGE, MA
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$27.62B

Shares outstanding$147.6M

52W high$202.41

52W low$115.25

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

BIIB

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Vertex Pharmaceuticals Q1 2026 Earnings Preview: Revenue Growth of 6.5% Expected

Apellis Pharmaceuticals, Inc. Files Form 8-K with SEC Detailing Company Information and Executive Provisions

Top 3 Health Care Stocks That May Collapse This Month

Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer

3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

New heart failure data on BridgeBio drug lands late-breaking ESC slot

BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026

Apellis (APLS) revises executive separation plan tied to Biogen merger

Biogen beats Q1 earnings estimates but cuts 2026 EPS view on M&A costs

Revvity Shareholders Re-Elect Board, Approve Bylaw Change; Exec Stock Retention Proposal Fails

FDA Action Alert: Argenx, AstraZeneca/Daiichi Sankyo, Biogen/Eisai and Cingulate

How Investors Are Reacting To Biogen (BIIB) Earnings Beat, Lower Guidance, And Felzartamab China Deal

How Investors Are Reacting To Biogen (BIIB) Earnings Beat, Lower Guidance, And Felzartamab China Deal

Biogen Inc. (BIIB) tops Q1 earnings and revenue estimates

Assessing Biohaven (BHVN) Valuation After Prolonged Share Price Weakness And Elevated P/B Ratio

PFA Pension Forsikringsaktieselskab Takes Position in Paychex, Inc. $PAYX

Kymera Advances STAT6 Degrader KT-621 in Phase 2b Atopic Dermatitis, Asthma Trials

BioMarin Pharmaceutical (BMRN) Reports Earnings Tomorrow: What To Expect

Vertex Pharmaceuticals (VRTX) Q1 Earnings: What To Expect

Is It Too Late To Consider Travere Therapeutics (TVTX) After Its Strong Share Price Rally?

About Biogen Inc

Classification

Company profile

BIIB

Market Comparison

BIIB Market Analysis

Overview

BIIB

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Vertex Pharmaceuticals Q1 2026 Earnings Preview: Revenue Growth of 6.5% Expected

Apellis Pharmaceuticals, Inc. Files Form 8-K with SEC Detailing Company Information and Executive Provisions

Top 3 Health Care Stocks That May Collapse This Month

Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer

3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

New heart failure data on BridgeBio drug lands late-breaking ESC slot

BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026

Apellis (APLS) revises executive separation plan tied to Biogen merger

Biogen beats Q1 earnings estimates but cuts 2026 EPS view on M&A costs

Revvity Shareholders Re-Elect Board, Approve Bylaw Change; Exec Stock Retention Proposal Fails

FDA Action Alert: Argenx, AstraZeneca/Daiichi Sankyo, Biogen/Eisai and Cingulate

How Investors Are Reacting To Biogen (BIIB) Earnings Beat, Lower Guidance, And Felzartamab China Deal

How Investors Are Reacting To Biogen (BIIB) Earnings Beat, Lower Guidance, And Felzartamab China Deal

Biogen Inc. (BIIB) tops Q1 earnings and revenue estimates

Assessing Biohaven (BHVN) Valuation After Prolonged Share Price Weakness And Elevated P/B Ratio

PFA Pension Forsikringsaktieselskab Takes Position in Paychex, Inc. $PAYX

Kymera Advances STAT6 Degrader KT-621 in Phase 2b Atopic Dermatitis, Asthma Trials

BioMarin Pharmaceutical (BMRN) Reports Earnings Tomorrow: What To Expect

Vertex Pharmaceuticals (VRTX) Q1 Earnings: What To Expect

Is It Too Late To Consider Travere Therapeutics (TVTX) After Its Strong Share Price Rally?

About Biogen Inc

Classification

Company profile

BIIB

Market Comparison